Heather Ralston

Heather Ralston

Auto-generated profile, based on publicly available information

Heather Ralston

Microplate Dx, Thomas Graham Building, 295 Cathedral Street, Glasgow G1 1XL, U.K.

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2026 in ACS Sensors
Verified
Journal Article
Open access
HRHeather Ralston
Heather Ralston
ABAdrian Butterworth
Adrian Butterworth
BCBen Clark
Ben Clark
MKMaria Katsafadou
Maria Katsafadou
VVVincent Vezza
Vincent Vezza
Damion CorriganDamion Corrigan
Damion Corrigan
Antimicrobial resistance poses a major global health threat, often driven by empirical antibiotic use due to the relatively slow (24-72 h) diagnostic pathway for urinary tract infections (UTIs). Due to their low cost and ease of multiplexing, electrochemical biosensors offer a promising alternative. Herein, we report on the Microplate Dx RapidPlate platform, a rapid electrochemical impedance spectroscopy (EIS)-based approach for accelerated antibiotic susceptibility testing (AST) directly from urine samples, without pre-treatment. This report charts the evolution of the core EIS-based AST measurement from a laboratory prototype into a fully realized Alpha prototype platform with an accompanying 32-channel electrochemical cartridge designed specifically for interrogation of urine samples. A total of 89 clinically derived urine samples were evaluated at three clinical sites (U.K. and India), with results compared against standard methods (VITEK 2 and disk diffusion). The impedance-based RapidPlate system detected bacterial growth within 50 min and provided susceptibility profiles by 85 min, with 95% concordance to reference tests. Consistent performance was demonstrated across diverse clinical settings and organisms, including Escherichia coli and Klebsiella pneumoniae. The RapidPlate AST system has demonstrated great potential as a cost-effective, point-of-care tool for rapid AST, supporting and improving UTI management and antimicrobial stewardship.

29 July 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
HRHeather Ralston
Heather Ralston
ABAdrian Butterworth
Adrian Butterworth
BCBen Clark
Ben Clark
MKMaria Katsafadou
Maria Katsafadou
VVVincent Vezza
Vincent Vezza
Damion CorriganDamion Corrigan
Damion Corrigan
Antimicrobial resistance (AMR) poses a major global health threat, often driven by empirical antibiotic use due to the relatively slow (24-72 hour) diagnostic pathway for urinary tract infections (UTIs). Due to their low cost and ease of multiplexing, electro-chemical biosensors offer a promising alternative. Herein, we report on the Microplate Dx RapidPlate™ platform, a rapid electrochemical impedance spectroscopy (EIS) based approach for accelerated antibiotic susceptibility testing (AST) directly from urine samples, without pre-treatment. This report charts the evolution of the core EIS based AST measurement from laboratory proto-type into fully realised Alpha prototype platform with an accompanying 32-channel electrochemical cartridge designed specifically for interrogation of urine samples. A total of 89 clinically derived urine samples were evaluated at three clinical sites (UK and India), with results compared against standard methods (VITEK 2 and disk diffusion). The impedance based RapidPlate™ system detected bacterial growth within 50 minutes and provided susceptibility profiles by 85 minutes, with 94% concordance to reference tests. Consistent performance is demonstrated across diverse clinical settings and organisms, including Escherichia coli and Klebsiella pneumoniae. The RapidPlate™ AST system has demonstrated great potential as a cost-effective, point-of-care tool for rapid AST, supporting and improving UTI management and antimicrobial stewardship.